Trial Profile

A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Participants With HIV-1, Who Are 4 Weeks to Less Than 12 Years of Age and Weigh Less Than 45 kg

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 08 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Doravirine (Primary) ; Doravirine/lamivudine/tenofovir disoproxil fumarate (Primary)
Indications HIV-1 infections
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Acronyms MK-1439-066
Sponsors Merck Sharp & Dohme Corp.

13 Aug 2023 Planned End Date changed from 3 Nov 2026 to 11 Apr 2034.
13 Aug 2023 Planned primary completion date changed from 3 Jun 2025 to 4 Mar 2028.
21 Jan 2021 Planned initiation date (estimated date for recruitment of the first subject) changed from 21 Dec 2020 to 03 Feb 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com